1-8 of 8
Yi Ren
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non–Small Cell Lung Cancer

Michael I. Barbato, Diana Bradford, Yi Ren, Stephanie L. Aungst, Claudia P. Miller, Lili Pan, Jeanne F. Zirkelbach, Yangbing Li, Youwei Bi, Jianghong Fan, Manuela Grimstein, Sarah E. Dorff, Anup K. Amatya, Pallavi S. Mishra-Kalyani, Barbara Scepura, Peter Schotland, Opeyemi Udoka, Idara Ojofeitimi, John K. Leighton, Nam A. Rahman, Richard Pazdur, Harpreet Singh, Paul G. Kluetz, Nicole Drezner
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (16): 3364–3370.
https://doi.org/10.1158/1078-0432.CCR-24-0949
Published: 15 August 2024
View article titled, FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non–Small Cell Lung Cancer
Open the PDF for FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non–Small Cell Lung Cancer in another window
Journal Articles

FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation–Positive Low-Grade Glioma

Michael I. Barbato, Jeannette Nashed, Diana Bradford, Yi Ren, Sachia Khasar, Claudia P. Miller, Banu S. Zolnik, Hong Zhao, Yangbing Li, Youwei Bi, Stacy S. Shord, Anup K. Amatya, Pallavi S. Mishra-Kalyani, Barbara Scepura, Raniya A. Al-Matari, Richard Pazdur, Paul G. Kluetz, Martha Donoghue, Harpreet Singh, Nicole Drezner
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (2): 263–268.
https://doi.org/10.1158/1078-0432.CCR-23-1503
Published: 17 January 2024
View article titled, FDA Approval Summary: Dabrafenib in Combination with Trametinib for <em>BRAF</em><sup>V600E</sup> Mutation–Positive Low-Grade Glioma
Open the PDF for FDA Approval Summary: Dabrafenib in Combination with Trametinib for <em>BRAF</em><sup>V600E</sup> Mutation–Positive Low-Grade Glioma in another window
Journal Articles

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

Sandra J. Casak, Shan Pradhan, Lola A. Fashoyin-Aje, Yi Ren, Yuan-Li Shen, Yuan Xu, Edwin Chiu Yuen Chow, Ye Xiong, Jeanne Fourie Zirklelbach, Jiang Liu, Rosane Charlab, William F. Pierce, Nataliya Fesenko, Julia A. Beaver, Richard Pazdur, Paul G. Kluetz, Steven J. Lemery
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2733–2737.
https://doi.org/10.1158/1078-0432.CCR-21-4462
Published: 01 July 2022
View article titled, FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation
Open the PDF for FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation in another window
Journal Articles

FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1–High NSCLC

Oladimeji Akinboro, Erin Larkins, Lee H. Pai-Scherf, Luckson N. Mathieu, Yi Ren, Joyce Cheng, Mallorie H. Fiero, Wentao Fu, Youwei Bi, Shyam Kalavar, Samina Jafri, Pallavi S. Mishra-Kalyani, Jeanne Fourie Zirkelbach, Hongshan Li, Hong Zhao, Kun He, Whitney S. Helms, Meredith K. Chuk, Min Wang, Ilynn Bulatao, Jonathan Herz, Blaire L. Osborn, Yuan Xu, Jiang Liu, Yutao Gong, Sharon Sickafuse, Rebecca Cohen, Martha Donoghue, Richard Pazdur, Julia A. Beaver, Harpreet Singh
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (11): 2221–2228.
https://doi.org/10.1158/1078-0432.CCR-21-3844
Published: 01 June 2022
View article titled, FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1–High NSCLC
Open the PDF for FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1–High NSCLC in another window
Journal Articles

Placental Growth Factor Upregulation Is a Host Response to Antiangiogenic Therapy

Rebecca G. Bagley, Yi Ren, William Weber, Min Yao, Leslie Kurtzberg, Jason Pinckney, Dinesh Bangari, Cokey Nguyen, William Brondyk, Johanne Kaplan, Beverly A. Teicher
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (5): 976–988.
https://doi.org/10.1158/1078-0432.CCR-10-2687
Published: 01 March 2011
View article titled, Placental Growth Factor Upregulation Is a Host Response to Antiangiogenic Therapy
Open the PDF for Placental Growth Factor Upregulation Is a Host Response to Antiangiogenic Therapy in another window
Journal Articles

Statistical Analysis of DNA Microarray Data in Cancer Research

Jianqing Fan, Yi Ren
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (15): 4469–4473.
https://doi.org/10.1158/1078-0432.CCR-06-1033
Published: 09 August 2006
View article titled, Statistical Analysis of DNA Microarray Data in Cancer Research
Open the PDF for Statistical Analysis of DNA Microarray Data in Cancer Research in another window
Journal Articles

Hepatocyte Growth Factor Promotes Cancer Cell Migration and Angiogenic Factors Expression: A Prognostic Marker of Human Esophageal Squamous Cell Carcinomas

Yi Ren, Brian Cao, Simon Law, Yi Xie, Ping Yin Lee, Leo Cheung, Yongxong Chen, Xin Huang, Hiu Man Chan, Ping Zhao, John Luk, George Vande Woude, John Wong
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (17): 6190–6197.
https://doi.org/10.1158/1078-0432.CCR-04-2553
Published: 06 September 2005
View article titled, Hepatocyte Growth Factor Promotes Cancer Cell Migration and Angiogenic Factors Expression: A Prognostic Marker of Human Esophageal Squamous Cell Carcinomas
Open the PDF for Hepatocyte Growth Factor Promotes Cancer Cell Migration and Angiogenic Factors Expression: A Prognostic Marker of Human Esophageal Squamous Cell Carcinomas in another window
Journal Articles

Interleukin-8 Serum Levels in Patients with Hepatocellular Carcinoma: Correlations with Clinicopathological Features and Prognosis

Yi Ren, Ronnie Tung-Ping Poon, Hong-Teng Tsui, Wen-Hong Chen, Zhi Li, Cecilia Lau, Wun-Ching Yu, Sheung-Tat Fan
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (16): 5996–6001.
Published: 15 December 2003
View article titled, Interleukin-8 Serum Levels in Patients with Hepatocellular Carcinoma: <subtitle>Correlations with Clinicopathological Features and Prognosis</subtitle>
Open the PDF for Interleukin-8 Serum Levels in Patients with Hepatocellular Carcinoma: <subtitle>Correlations with Clinicopathological Features and Prognosis</subtitle> in another window